Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
65,901.91 -795.59 (-1.19%) CMC Crypto 200
1,423.22 +5.34 (+0.39%)
GILD Jan 2026 70.000 call
| Previous close | 5.05 |
| Open | 5.92 |
| Bid | 5.70 |
| Ask | 7.00 |
| Strike | 70.00 |
| Expiry date | 2026-01-16 |
| Day's range | 5.92 - 6.18 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.03k |
Barrons.comGilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.
Gilead Sciences stock was climbing Friday on hopes that it would get into the obesity-drug game. GLP-1s, the technical name for the popular obesity drugs, has been one of the biggest drivers of pharmaceutical stocks in recent months. Which may be why Gilead stock has gained 2.8% to $64.55 in afternoon trading Friday after Jefferies released a note late Thursday night.
GuruFocus.comGilead Sciences Inc's Dividend Analysis
Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.77 per share, payable on 2024-06-27, with the ex-dividend date set for 2024-06-14. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Gilead Sciences Inc's dividend performance and assess its sustainability.
Business WireNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co
